Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol-Reference-Cited by-同舟云学术

Adding liraglutide to the backbone therapy of biguanide in patients with coronary artery disease and newly diagnosed type-2 diabetes (the AddHope2 study): a randomised controlled study protocol

Published:2014-07-16 Issue:7 Volume:4 Page:e005942-e005942
ISSN:2044-6055
Container-title:BMJ Open
language:en
Short-container-title:BMJ Open

Author:

Anholm C.,Kumarathurai P.,Klit M. S.,Kristiansen O. P.,Nielsen O. W.,Ladelund S.,Madsbad S.,Sajadieh A.,Haugaard S. B.,Lange C.,Holst J. J.,Molvig J.,Deacon C.,Fenger M.,Andersen O.,Boston R.

Publisher

BMJ

Subject

General Medicine

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis;Cochrane Database of Systematic Reviews;2021-10-25

2. Effects of liraglutide on diastolic function parameters in patients with type 2 diabetes and coronary artery disease: a randomized crossover study;Cardiovascular Diabetology;2021-01-07

3. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial;Atherosclerosis;2019-09

4. Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease;Diabetology & Metabolic Syndrome;2019-05-31

5. Alterations in plasma non-esterified fatty acid (NEFA) kinetics and relationship with insulin resistance in polycystic ovary syndrome;Human Reproduction;2018-12-20